Business Context and Reporting Period
This Form 8-K Current Report was filed by GRI Bio, Inc. on July 31, 2025. The Company, incorporated in Delaware and trading on the Nasdaq Capital Market under the symbol "GRI," is an emerging growth company. The report primarily addresses a corporate event regarding clinical trial progress rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or quantitative financial data.
Material Changes
The material change disclosed is the release of interim biomarker data from the Company's ongoing Phase 2a study evaluating GRI-0621 for the treatment of idiopathic pulmonary fibrosis. This data was announced via a press release issued on July 31, 2025.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the interim biomarker data. The filing does not contain specific forward-looking guidance, updated financial outlooks, or detailed risk factors beyond the standard implications of clinical trial results. The full details of the data and its implications are contained in the press release filed as Exhibit 99.1.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) to understand the specific interim biomarker results for GRI-0621.
- Verify the clinical significance of the biomarker data in the context of idiopathic pulmonary fibrosis treatment.
- Check subsequent filings for any updates on the Phase 2a study timeline or potential regulatory interactions.
- Confirm the Company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K does not provide liquidity data.